Vibe GrowthFRA:3ST0 +0.43%29 EBITDA Margin % is 4.93% as of Mar. 2026. GuruFocus rates FRA:3ST0 with a GF Score™ of 29/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Vibe Growth ranks worse than 71.94% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vibe Growth's EBITDA for the
three
months ended in Mar. 2026 was €0.19 Mil. Vibe Growth's Revenue for the
three
months ended in Mar. 2026 was €3.89 Mil. Therefore, Vibe Growth's EBITDA margin for the quarter that ended in Mar. 2026 was 4.93%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vibe Growth EBITDA Margin % Related Terms
Vibe Growth EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vibe Growth's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vibe Growth's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vibe Growth EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vibe Growth's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vibe Growth's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vibe Growth (FRA:3ST0) has a EBITDA Margin % of 4.93% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vibe Growth and its competitors. According to the industry distribution chart, Vibe Growth ranks #687 out of 955 companies in the Drug Manufacturers industry, placing it in the top 71.9%.
Is Vibe Growth's EBITDA Margin % too high?
Vibe Growth's current EBITDA Margin % is 4.93%. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Vibe Growth's value of 4.93% is 60.2% below this industry median. Based on the distribution chart, Vibe Growth ranks #687 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vibe Growth has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vibe Growth's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vibe Growth ranks #687 out of 955 companies for EBITDA Margin %. This places Vibe Growth in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Vibe Growth's value of 4.93% is 60.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vibe Growth's current EBITDA Margin % of 4.93% is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vibe Growth and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vibe Growth's current EBITDA Margin % is 4.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vibe Growth stock overvalued right now?
Based on GuruFocus' analysis, Vibe Growth (FRA:3ST0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.23 — trading 191.3% above its estimated fair value. The current EBITDA Margin % is 4.93% and 60.2% below the Drug Manufacturers industry median of 12.39. Vibe Growth's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vibe Growth (FRA:3ST0), the current EBITDA Margin % is 4.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vibe Growth (FRA:3ST0) Overvalued in 2026?
Based on GuruFocus' analysis, Vibe Growth stock appears to be overvalued.
The current stock price of €0.23 is trading 191.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Vibe Growth to be Significantly Overvalued.
Key valuation signals for FRA:3ST0:
EBITDA Margin %: 4.93%
GF Value™: €0.08 vs. price of €0.23 (191.3% above fair value)
Industry Position: 60.2% below the Drug Manufacturers median (#687 of 955)
No single metric tells the full story. See the FRA:3ST0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vibe Growth Corp is engaged in the evaluation, acquisition, and development of cannabis cultivation, distribution, and manufacturing assets and retail cannabis dispensaries, predominantly in the U.S., to become a vertically integrated cannabis operator. The company currently operates four dispensaries, one distribution, and one cultivation operation in the State of California, plus one dispensary in Portland, Oregon. It offers cannabis infused products across various categories such as vaporizers, concentrates, edibles, topicals, pre-rolls, etc., and through different brands including Alien Labs, Almora Farm, Buddies, Chill Bud, Highatus, and Others.
29GF Score
Get the complete analysis for FRA:3ST0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3ST0 has been successfully added to your 
